Literature DB >> 20665931

Prostate cancer: time to trial statins?

Suzanne J Farley.   

Abstract

Entities:  

Year:  2010        PMID： 20665931     DOI： 10.1038/nrurol.2010.85

Source DB:  PubMed          Journal:  Nat Rev Urol        ISSN： 1759-4812            Impact factor:   14.432


× No keyword cloud information.
  3 in total

1.  Improved biochemical outcomes with statin use in patients with high-risk localized prostate cancer treated with radiotherapy.

Authors:  Marisa A Kollmeier; Matthew S Katz; Kimberley Mak; Yoshiya Yamada; David J Feder; Zhigang Zhang; Xiaoyu Jia; Weiji Shi; Michael J Zelefsky
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-05-06       Impact factor: 7.038

2.  Statin use and risk of prostate cancer recurrence in men treated with radiation therapy.

Authors:  Ruchika Gutt; Nathan Tonlaar; Rangesh Kunnavakkam; Theodore Karrison; Ralph R Weichselbaum; Stanley L Liauw
Journal:  J Clin Oncol       Date:  2010-04-26       Impact factor: 44.544

3.  Rosuvastatin, identified from a zebrafish chemical genetic screen for antiangiogenic compounds, suppresses the growth of prostate cancer.

Authors:  Chunyang Wang; Weiyang Tao; Youdong Wang; Jennifer Bikow; Bingxin Lu; Armand Keating; Subodh Verma; Thomas G Parker; Ruifa Han; Xiao-Yan Wen
Journal:  Eur Urol       Date:  2010-05-22       Impact factor: 20.096
  3 in total
  1 in total

1.  Altered expression of farnesyl pyrophosphate synthase in prostate cancer: evidence for a role of the mevalonate pathway in disease progression?

Authors:  Tilman Todenhöfer; Jörg Hennenlotter; Ursula Kühs; Valentina Gerber; Georgios Gakis; Ulrich Vogel; Stefan Aufderklamm; Axel Merseburger; Judith Knapp; Arnulf Stenzl; Christian Schwentner
Journal:  World J Urol       Date:  2012-03-11       Impact factor: 4.226
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.